title: Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).
abstract: OBJECTIVE
  We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social interactions, satisfaction with sexual relationships, days in bed, days with restricted activity and overall satisfaction with health status. The FSQ was compared to the Minnesota Living with Heart Failure questionnaire (MLwHF).
  
  
  RESULTS
  The FSQ was evaluated in a substudy (n = 340) of the second Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II), a placebo-controlled mortality trial. 265 patients (75%) patients completed both questionnaires at 6 months of follow-up. Both questionnaires indicated substantially impaired QoL. The FSQ demonstrated high internal consistency (Cronbach's α > 0.7 for all items except "social activity" = 0.66) and construct and concurrent validity. After 6 months, the only item on either questionnaire to show a difference between the placebo- and bisoprolol-treatment groups was the single item FSQ question about "days in bed" (p = 0.018 in favour of bisoprolol).
  
  
  CONCLUSIONS
  The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.
authors.affiliation: BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Scotland, UK.
authors.forename: Siobhan
authors.initials: S
authors.lastname: Gallanagh
authors.forename: Davide
authors.initials: D
authors.lastname: Castagno
authors.forename: Ben
authors.initials: B
authors.lastname: Wilson
authors.forename: Erland
authors.initials: E
authors.lastname: Erdmann
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
authors.forename: Willem J
authors.initials: WJ
authors.lastname: Remme
authors.forename: José L
authors.initials: JL
authors.lastname: Lopez-Sendon
authors.forename: Philippe
authors.initials: P
authors.lastname: Lechat
authors.forename: Ferenc
authors.initials: F
authors.lastname: Follath
authors.forename: Christer
authors.initials: C
authors.lastname: Höglund
authors.forename: Viacheslav
authors.initials: V
authors.lastname: Mareev
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Sadowski
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Seabra-Gomes
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Dargie
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
mesh_terms: D017298:Bisoprolol / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D008875:Middle Aged; D008910:Minnesota; D010919:Placebos; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014937:Work
chemical_list: D010919:Placebos; D017298:Bisoprolol